nodes	percent_of_prediction	percent_of_DWPC	metapath
Tiludronate—PTPN1—nephron tubule—kidney cancer	0.0299	0.119	CbGeAlD
Tiludronate—PTPN1—renal system—kidney cancer	0.0272	0.108	CbGeAlD
Tiludronate—PTPN1—kidney—kidney cancer	0.0263	0.104	CbGeAlD
Tiludronate—PTPN1—cortex of kidney—kidney cancer	0.0256	0.102	CbGeAlD
Tiludronate—PTPN1—gonad—kidney cancer	0.0244	0.0967	CbGeAlD
Tiludronate—PTPN1—cardiac atrium—kidney cancer	0.0244	0.0965	CbGeAlD
Tiludronate—ATP6V1A—nephron tubule—kidney cancer	0.0179	0.071	CbGeAlD
Tiludronate—ATP6V1A—renal system—kidney cancer	0.0163	0.0646	CbGeAlD
Tiludronate—ATP6V1A—kidney—kidney cancer	0.0158	0.0624	CbGeAlD
Tiludronate—ATP6V1A—cortex of kidney—kidney cancer	0.0154	0.0608	CbGeAlD
Tiludronate—ATP6V1A—gonad—kidney cancer	0.0146	0.0579	CbGeAlD
Tiludronate—ATP6V1A—cardiac atrium—kidney cancer	0.0146	0.0578	CbGeAlD
Tiludronate—Developmental delay—Capecitabine—kidney cancer	0.00767	0.023	CcSEcCtD
Tiludronate—Congenital anomaly—Capecitabine—kidney cancer	0.00767	0.023	CcSEcCtD
Tiludronate—Bone pain—Vinblastine—kidney cancer	0.00664	0.0199	CcSEcCtD
Tiludronate—Bone pain—Erlotinib—kidney cancer	0.00638	0.0191	CcSEcCtD
Tiludronate—Influenza-like symptoms—Gemcitabine—kidney cancer	0.00594	0.0178	CcSEcCtD
Tiludronate—Bone pain—Sunitinib—kidney cancer	0.00552	0.0165	CcSEcCtD
Tiludronate—Influenza like illness—Sorafenib—kidney cancer	0.00534	0.016	CcSEcCtD
Tiludronate—Influenza like illness—Sunitinib—kidney cancer	0.00514	0.0154	CcSEcCtD
Tiludronate—Influenza-like symptoms—Paclitaxel—kidney cancer	0.00498	0.0149	CcSEcCtD
Tiludronate—Bone pain—Vincristine—kidney cancer	0.00467	0.014	CcSEcCtD
Tiludronate—Bone pain—Gemcitabine—kidney cancer	0.00443	0.0133	CcSEcCtD
Tiludronate—Rhinitis—Temsirolimus—kidney cancer	0.00429	0.0128	CcSEcCtD
Tiludronate—Influenza like illness—Gemcitabine—kidney cancer	0.00412	0.0123	CcSEcCtD
Tiludronate—Bone pain—Paclitaxel—kidney cancer	0.00371	0.0111	CcSEcCtD
Tiludronate—Back pain—Temsirolimus—kidney cancer	0.0036	0.0108	CcSEcCtD
Tiludronate—Influenza like illness—Paclitaxel—kidney cancer	0.00345	0.0103	CcSEcCtD
Tiludronate—Rhinitis—Everolimus—kidney cancer	0.00319	0.00954	CcSEcCtD
Tiludronate—Myalgia—Temsirolimus—kidney cancer	0.00317	0.00949	CcSEcCtD
Tiludronate—Arthralgia—Temsirolimus—kidney cancer	0.00317	0.00949	CcSEcCtD
Tiludronate—Bone pain—Capecitabine—kidney cancer	0.00305	0.00911	CcSEcCtD
Tiludronate—Arthralgia—Pazopanib—kidney cancer	0.00299	0.00894	CcSEcCtD
Tiludronate—Myalgia—Pazopanib—kidney cancer	0.00299	0.00894	CcSEcCtD
Tiludronate—Influenza like illness—Capecitabine—kidney cancer	0.00283	0.00848	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Temsirolimus—kidney cancer	0.00277	0.00828	CcSEcCtD
Tiludronate—Back pain—Everolimus—kidney cancer	0.00268	0.00802	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Pazopanib—kidney cancer	0.00261	0.0078	CcSEcCtD
Tiludronate—Pain—Temsirolimus—kidney cancer	0.0026	0.00778	CcSEcCtD
Tiludronate—Back pain—Erlotinib—kidney cancer	0.00258	0.00773	CcSEcCtD
Tiludronate—Dyspepsia—Pazopanib—kidney cancer	0.00252	0.00754	CcSEcCtD
Tiludronate—Vertigo—Vinblastine—kidney cancer	0.0025	0.00747	CcSEcCtD
Tiludronate—Gastrointestinal pain—Temsirolimus—kidney cancer	0.00248	0.00744	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CDH1—kidney cancer	0.00245	0.00593	CbGpPWpGaD
Tiludronate—Pain—Pazopanib—kidney cancer	0.00245	0.00733	CcSEcCtD
Tiludronate—Abdominal pain—Temsirolimus—kidney cancer	0.0024	0.00719	CcSEcCtD
Tiludronate—PTPN1—Interferon Signaling—EGR1—kidney cancer	0.00239	0.00578	CbGpPWpGaD
Tiludronate—PTPN1—N-cadherin signaling events—PIK3CA—kidney cancer	0.00236	0.00571	CbGpPWpGaD
Tiludronate—Myalgia—Everolimus—kidney cancer	0.00236	0.00706	CcSEcCtD
Tiludronate—Arthralgia—Everolimus—kidney cancer	0.00236	0.00706	CcSEcCtD
Tiludronate—Gastrointestinal pain—Pazopanib—kidney cancer	0.00234	0.007	CcSEcCtD
Tiludronate—PTPN1—Interferon Signaling—IFNA2—kidney cancer	0.00232	0.00562	CbGpPWpGaD
Tiludronate—Myalgia—Erlotinib—kidney cancer	0.00227	0.00681	CcSEcCtD
Tiludronate—Arthralgia—Erlotinib—kidney cancer	0.00227	0.00681	CcSEcCtD
Tiludronate—Abdominal pain—Pazopanib—kidney cancer	0.00226	0.00677	CcSEcCtD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—TSC2—kidney cancer	0.00224	0.00542	CbGpPWpGaD
Tiludronate—Back pain—Sunitinib—kidney cancer	0.00224	0.0067	CcSEcCtD
Tiludronate—PTPN1—Leptin signaling pathway—RAF1—kidney cancer	0.0022	0.00533	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—RELA—kidney cancer	0.00219	0.00531	CbGpPWpGaD
Tiludronate—Asthenia—Temsirolimus—kidney cancer	0.00218	0.00652	CcSEcCtD
Tiludronate—PTPN1—Leptin signaling pathway—ERBB2—kidney cancer	0.00218	0.00527	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by TCPTP—PIK3CA—kidney cancer	0.00217	0.00524	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—MTOR—kidney cancer	0.00215	0.0052	CbGpPWpGaD
Tiludronate—Rhinitis—Gemcitabine—kidney cancer	0.00214	0.0064	CcSEcCtD
Tiludronate—PTPN1—Insulin Signaling—IGF1R—kidney cancer	0.00211	0.00511	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—ANXA2—kidney cancer	0.0021	0.00509	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—ASB15—kidney cancer	0.0021	0.00508	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—RAF1—kidney cancer	0.00209	0.00506	CbGpPWpGaD
Tiludronate—Diarrhoea—Temsirolimus—kidney cancer	0.00208	0.00622	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Everolimus—kidney cancer	0.00206	0.00616	CcSEcCtD
Tiludronate—Asthenia—Pazopanib—kidney cancer	0.00205	0.00615	CcSEcCtD
Tiludronate—Arthralgia—Sorafenib—kidney cancer	0.00205	0.00612	CcSEcCtD
Tiludronate—Myalgia—Sorafenib—kidney cancer	0.00205	0.00612	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MTOR—kidney cancer	0.00204	0.00494	CbGpPWpGaD
Tiludronate—Dizziness—Temsirolimus—kidney cancer	0.00201	0.00601	CcSEcCtD
Tiludronate—Dyspepsia—Everolimus—kidney cancer	0.00199	0.00595	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Erlotinib—kidney cancer	0.00199	0.00595	CcSEcCtD
Tiludronate—PTPN1—Insulin Pathway—PIK3CA—kidney cancer	0.00197	0.00477	CbGpPWpGaD
Tiludronate—Myalgia—Sunitinib—kidney cancer	0.00197	0.00589	CcSEcCtD
Tiludronate—Arthralgia—Sunitinib—kidney cancer	0.00197	0.00589	CcSEcCtD
Tiludronate—Bone pain—Doxorubicin—kidney cancer	0.00196	0.00587	CcSEcCtD
Tiludronate—Diarrhoea—Pazopanib—kidney cancer	0.00196	0.00586	CcSEcCtD
Tiludronate—Pain—Vinblastine—kidney cancer	0.00194	0.00581	CcSEcCtD
Tiludronate—Pain—Everolimus—kidney cancer	0.00193	0.00578	CcSEcCtD
Tiludronate—PTPN1—Leptin signaling pathway—CCND1—kidney cancer	0.00193	0.00466	CbGpPWpGaD
Tiludronate—Dyspepsia—Erlotinib—kidney cancer	0.00192	0.00574	CcSEcCtD
Tiludronate—Headache—Temsirolimus—kidney cancer	0.0019	0.0057	CcSEcCtD
Tiludronate—Dizziness—Pazopanib—kidney cancer	0.00189	0.00566	CcSEcCtD
Tiludronate—Back pain—Vincristine—kidney cancer	0.00189	0.00566	CcSEcCtD
Tiludronate—Pain—Erlotinib—kidney cancer	0.00186	0.00558	CcSEcCtD
Tiludronate—Myalgia—Dactinomycin—kidney cancer	0.00186	0.00558	CcSEcCtD
Tiludronate—Gastrointestinal pain—Vinblastine—kidney cancer	0.00186	0.00555	CcSEcCtD
Tiludronate—Gastrointestinal pain—Everolimus—kidney cancer	0.00185	0.00553	CcSEcCtD
Tiludronate—Influenza like illness—Doxorubicin—kidney cancer	0.00183	0.00546	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—JUN—kidney cancer	0.00182	0.00441	CbGpPWpGaD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.00182	0.0044	CbGpPWpGaD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.00182	0.0044	CbGpPWpGaD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.00182	0.0044	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CTNNB1—kidney cancer	0.00181	0.00438	CbGpPWpGaD
Tiludronate—Nausea—Temsirolimus—kidney cancer	0.0018	0.0054	CcSEcCtD
Tiludronate—Back pain—Gemcitabine—kidney cancer	0.0018	0.00537	CcSEcCtD
Tiludronate—Abdominal pain—Vinblastine—kidney cancer	0.00179	0.00537	CcSEcCtD
Tiludronate—Headache—Pazopanib—kidney cancer	0.00179	0.00537	CcSEcCtD
Tiludronate—Rhinitis—Paclitaxel—kidney cancer	0.00179	0.00536	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.00179	0.00535	CcSEcCtD
Tiludronate—Abdominal pain—Everolimus—kidney cancer	0.00179	0.00535	CcSEcCtD
Tiludronate—Gastrointestinal pain—Erlotinib—kidney cancer	0.00178	0.00534	CcSEcCtD
Tiludronate—Vertigo—Vincristine—kidney cancer	0.00176	0.00526	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by PTP1B—PIK3CA—kidney cancer	0.00176	0.00425	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—BRAF—kidney cancer	0.00175	0.00424	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—KCNMA1—kidney cancer	0.00174	0.00421	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—TSC2—kidney cancer	0.00173	0.00419	CbGpPWpGaD
Tiludronate—Dyspepsia—Sorafenib—kidney cancer	0.00173	0.00517	CcSEcCtD
Tiludronate—Abdominal pain—Erlotinib—kidney cancer	0.00172	0.00516	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.00172	0.00515	CcSEcCtD
Tiludronate—Nausea—Pazopanib—kidney cancer	0.0017	0.00509	CcSEcCtD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—IGF2—kidney cancer	0.00169	0.00408	CbGpPWpGaD
Tiludronate—Pain—Sorafenib—kidney cancer	0.00168	0.00502	CcSEcCtD
Tiludronate—Myalgia—Vincristine—kidney cancer	0.00167	0.00498	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—IFNA1—kidney cancer	0.00166	0.00403	CbGpPWpGaD
Tiludronate—Dyspepsia—Sunitinib—kidney cancer	0.00166	0.00497	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.00163	0.00487	CcSEcCtD
Tiludronate—Asthenia—Vinblastine—kidney cancer	0.00163	0.00487	CcSEcCtD
Tiludronate—Asthenia—Everolimus—kidney cancer	0.00162	0.00485	CcSEcCtD
Tiludronate—Pain—Sunitinib—kidney cancer	0.00161	0.00483	CcSEcCtD
Tiludronate—Gastrointestinal pain—Sorafenib—kidney cancer	0.0016	0.0048	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—EGR1—kidney cancer	0.0016	0.00386	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CUL7—kidney cancer	0.00159	0.00385	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—MAPK3—kidney cancer	0.00159	0.00384	CbGpPWpGaD
Tiludronate—Myalgia—Gemcitabine—kidney cancer	0.00158	0.00473	CcSEcCtD
Tiludronate—Arthralgia—Gemcitabine—kidney cancer	0.00158	0.00473	CcSEcCtD
Tiludronate—Asthenia—Erlotinib—kidney cancer	0.00156	0.00468	CcSEcCtD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—RAF1—kidney cancer	0.00155	0.00376	CbGpPWpGaD
Tiludronate—Diarrhoea—Vinblastine—kidney cancer	0.00155	0.00465	CcSEcCtD
Tiludronate—Abdominal pain—Sorafenib—kidney cancer	0.00155	0.00464	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—IFNA2—kidney cancer	0.00155	0.00375	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—CCBL1—kidney cancer	0.00155	0.00375	CbGpPWpGaD
Tiludronate—Diarrhoea—Everolimus—kidney cancer	0.00155	0.00463	CcSEcCtD
Tiludronate—Gastrointestinal pain—Sunitinib—kidney cancer	0.00154	0.00462	CcSEcCtD
Tiludronate—Pain—Dactinomycin—kidney cancer	0.00153	0.00457	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—GRB7—kidney cancer	0.00152	0.00368	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—MTOR—kidney cancer	0.00152	0.00367	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—MAPK1—kidney cancer	0.00151	0.00366	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MAPK3—kidney cancer	0.00151	0.00365	CbGpPWpGaD
Tiludronate—Back pain—Paclitaxel—kidney cancer	0.0015	0.0045	CcSEcCtD
Tiludronate—Dizziness—Vinblastine—kidney cancer	0.0015	0.00449	CcSEcCtD
Tiludronate—Dizziness—Everolimus—kidney cancer	0.00149	0.00447	CcSEcCtD
Tiludronate—Abdominal pain—Sunitinib—kidney cancer	0.00149	0.00447	CcSEcCtD
Tiludronate—Diarrhoea—Erlotinib—kidney cancer	0.00149	0.00447	CcSEcCtD
Tiludronate—Rhinitis—Capecitabine—kidney cancer	0.00147	0.00439	CcSEcCtD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—RAF1—kidney cancer	0.00146	0.00354	CbGpPWpGaD
Tiludronate—Gastrointestinal pain—Dactinomycin—kidney cancer	0.00146	0.00437	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00145	0.00435	CcSEcCtD
Tiludronate—PTPN1—Immune System—SRMS—kidney cancer	0.00145	0.00352	CbGpPWpGaD
Tiludronate—Dizziness—Erlotinib—kidney cancer	0.00144	0.00432	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MAPK1—kidney cancer	0.00143	0.00347	CbGpPWpGaD
Tiludronate—Headache—Vinblastine—kidney cancer	0.00142	0.00425	CcSEcCtD
Tiludronate—Headache—Everolimus—kidney cancer	0.00142	0.00424	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—ITPR2—kidney cancer	0.00141	0.00342	CbGpPWpGaD
Tiludronate—Abdominal pain—Dactinomycin—kidney cancer	0.00141	0.00423	CcSEcCtD
Tiludronate—Asthenia—Sorafenib—kidney cancer	0.00141	0.00421	CcSEcCtD
Tiludronate—ATP6V1A—Disease—AMER1—kidney cancer	0.0014	0.00339	CbGpPWpGaD
Tiludronate—Vertigo—Paclitaxel—kidney cancer	0.0014	0.00418	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.00138	0.00413	CcSEcCtD
Tiludronate—Headache—Erlotinib—kidney cancer	0.00137	0.00409	CcSEcCtD
Tiludronate—Pain—Vincristine—kidney cancer	0.00137	0.00409	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—OR4C13—kidney cancer	0.00136	0.00328	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—OR4C13—kidney cancer	0.00136	0.00328	CbGpPWpGaD
Tiludronate—Asthenia—Sunitinib—kidney cancer	0.00135	0.00405	CcSEcCtD
Tiludronate—Nausea—Vinblastine—kidney cancer	0.00135	0.00403	CcSEcCtD
Tiludronate—Nausea—Everolimus—kidney cancer	0.00134	0.00402	CcSEcCtD
Tiludronate—Diarrhoea—Sorafenib—kidney cancer	0.00134	0.00402	CcSEcCtD
Tiludronate—Arthralgia—Paclitaxel—kidney cancer	0.00132	0.00396	CcSEcCtD
Tiludronate—Myalgia—Paclitaxel—kidney cancer	0.00132	0.00396	CcSEcCtD
Tiludronate—Gastrointestinal pain—Vincristine—kidney cancer	0.00131	0.00391	CcSEcCtD
Tiludronate—Dizziness—Sorafenib—kidney cancer	0.0013	0.00388	CcSEcCtD
Tiludronate—Pain—Gemcitabine—kidney cancer	0.0013	0.00388	CcSEcCtD
Tiludronate—Nausea—Erlotinib—kidney cancer	0.0013	0.00388	CcSEcCtD
Tiludronate—Diarrhoea—Sunitinib—kidney cancer	0.00129	0.00387	CcSEcCtD
Tiludronate—Asthenia—Dactinomycin—kidney cancer	0.00128	0.00384	CcSEcCtD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—JUN—kidney cancer	0.00128	0.00309	CbGpPWpGaD
Tiludronate—Abdominal pain—Vincristine—kidney cancer	0.00126	0.00378	CcSEcCtD
Tiludronate—Dizziness—Sunitinib—kidney cancer	0.00125	0.00374	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—PIK3CA—kidney cancer	0.00124	0.00301	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—PTEN—kidney cancer	0.00123	0.00299	CbGpPWpGaD
Tiludronate—Back pain—Capecitabine—kidney cancer	0.00123	0.00369	CcSEcCtD
Tiludronate—Headache—Sorafenib—kidney cancer	0.00123	0.00368	CcSEcCtD
Tiludronate—Diarrhoea—Dactinomycin—kidney cancer	0.00122	0.00366	CcSEcCtD
Tiludronate—PTPN1—Immune System—CD274—kidney cancer	0.00121	0.00292	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—RAF1—kidney cancer	0.0012	0.00291	CbGpPWpGaD
Tiludronate—Headache—Sunitinib—kidney cancer	0.00118	0.00354	CcSEcCtD
Tiludronate—ATP6V1A—Disease—GPC3—kidney cancer	0.00117	0.00284	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—MTOR—kidney cancer	0.00117	0.00284	CbGpPWpGaD
Tiludronate—Nausea—Sorafenib—kidney cancer	0.00117	0.00349	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.00116	0.00346	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—LATS1—kidney cancer	0.00115	0.00279	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—LATS1—kidney cancer	0.00115	0.00279	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—VHL—kidney cancer	0.00115	0.00278	CbGpPWpGaD
Tiludronate—Vertigo—Capecitabine—kidney cancer	0.00115	0.00343	CcSEcCtD
Tiludronate—Asthenia—Vincristine—kidney cancer	0.00115	0.00343	CcSEcCtD
Tiludronate—Nausea—Sunitinib—kidney cancer	0.00112	0.00336	CcSEcCtD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—MAPK3—kidney cancer	0.00112	0.00271	CbGpPWpGaD
Tiludronate—Dyspepsia—Paclitaxel—kidney cancer	0.00112	0.00334	CcSEcCtD
Tiludronate—PTPN1—Immune System—TXNIP—kidney cancer	0.0011	0.00267	CbGpPWpGaD
Tiludronate—Diarrhoea—Vincristine—kidney cancer	0.00109	0.00327	CcSEcCtD
Tiludronate—Asthenia—Gemcitabine—kidney cancer	0.00109	0.00325	CcSEcCtD
Tiludronate—ATP6V1A—Disease—ST3GAL2—kidney cancer	0.00109	0.00263	CbGpPWpGaD
Tiludronate—Myalgia—Capecitabine—kidney cancer	0.00109	0.00325	CcSEcCtD
Tiludronate—Arthralgia—Capecitabine—kidney cancer	0.00109	0.00325	CcSEcCtD
Tiludronate—Pain—Paclitaxel—kidney cancer	0.00108	0.00325	CcSEcCtD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—MAPK1—kidney cancer	0.00107	0.00258	CbGpPWpGaD
Tiludronate—Nausea—Dactinomycin—kidney cancer	0.00106	0.00318	CcSEcCtD
Tiludronate—Dizziness—Vincristine—kidney cancer	0.00106	0.00316	CcSEcCtD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—MAPK3—kidney cancer	0.00106	0.00255	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—JUN—kidney cancer	0.00105	0.00254	CbGpPWpGaD
Tiludronate—Gastrointestinal pain—Paclitaxel—kidney cancer	0.00104	0.0031	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—IFNA1—kidney cancer	0.00104	0.00251	CbGpPWpGaD
Tiludronate—Diarrhoea—Gemcitabine—kidney cancer	0.00104	0.0031	CcSEcCtD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—MYC—kidney cancer	0.00103	0.00248	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—PGK1—kidney cancer	0.00102	0.00246	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—SLC5A3—kidney cancer	0.00102	0.00246	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—PTEN—kidney cancer	0.00101	0.00245	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—TCEB2—kidney cancer	0.00101	0.00244	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—TCEB1—kidney cancer	0.00101	0.00244	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—KRAS—kidney cancer	0.00101	0.00244	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—MAPK1—kidney cancer	0.001	0.00243	CbGpPWpGaD
Tiludronate—Abdominal pain—Paclitaxel—kidney cancer	0.001	0.003	CcSEcCtD
Tiludronate—Headache—Vincristine—kidney cancer	0.001	0.00299	CcSEcCtD
Tiludronate—ATP6V1A—Disease—LDHB—kidney cancer	0.000998	0.00241	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—SFRP2—kidney cancer	0.000998	0.00241	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—AMER1—kidney cancer	0.000981	0.00237	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—AMER1—kidney cancer	0.000981	0.00237	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—IFNA2—kidney cancer	0.000965	0.00234	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—KEAP1—kidney cancer	0.000963	0.00233	CbGpPWpGaD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.00096	0.00232	CbGpPWpGaD
Tiludronate—Headache—Gemcitabine—kidney cancer	0.000949	0.00284	CcSEcCtD
Tiludronate—Nausea—Vincristine—kidney cancer	0.000949	0.00284	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000948	0.00284	CcSEcCtD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—KRAS—kidney cancer	0.000948	0.00229	CbGpPWpGaD
Tiludronate—Rhinitis—Doxorubicin—kidney cancer	0.000947	0.00283	CcSEcCtD
Tiludronate—ATP6V1A—Disease—TCEB1—kidney cancer	0.000931	0.00225	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—TCEB2—kidney cancer	0.000931	0.00225	CbGpPWpGaD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—RAF1—kidney cancer	0.000928	0.00224	CbGpPWpGaD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000927	0.00224	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—PIK3CA—kidney cancer	0.000925	0.00224	CbGpPWpGaD
Tiludronate—Dyspepsia—Capecitabine—kidney cancer	0.000916	0.00274	CcSEcCtD
Tiludronate—Asthenia—Paclitaxel—kidney cancer	0.00091	0.00272	CcSEcCtD
Tiludronate—Nausea—Gemcitabine—kidney cancer	0.0009	0.00269	CcSEcCtD
Tiludronate—Pain—Capecitabine—kidney cancer	0.00089	0.00266	CcSEcCtD
Tiludronate—PTPN1—Immune System—CASP2—kidney cancer	0.000871	0.00211	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—PIK3CA—kidney cancer	0.000871	0.00211	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—IGF2—kidney cancer	0.000869	0.0021	CbGpPWpGaD
Tiludronate—Diarrhoea—Paclitaxel—kidney cancer	0.000868	0.0026	CcSEcCtD
Tiludronate—PTPN1—Insulin Signaling—MAPK3—kidney cancer	0.000866	0.0021	CbGpPWpGaD
Tiludronate—Gastrointestinal pain—Capecitabine—kidney cancer	0.000851	0.00255	CcSEcCtD
Tiludronate—Dizziness—Paclitaxel—kidney cancer	0.000839	0.00251	CcSEcCtD
Tiludronate—PTPN1—Immune System—CD34—kidney cancer	0.000835	0.00202	CbGpPWpGaD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—IL2—kidney cancer	0.000832	0.00201	CbGpPWpGaD
Tiludronate—PTPN1—Interferon Signaling—MAPK3—kidney cancer	0.000829	0.00201	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—MAPK1—kidney cancer	0.000824	0.00199	CbGpPWpGaD
Tiludronate—Abdominal pain—Capecitabine—kidney cancer	0.000823	0.00246	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—GPC3—kidney cancer	0.000822	0.00199	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CER1—kidney cancer	0.000822	0.00199	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—GPC3—kidney cancer	0.000822	0.00199	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CER1—kidney cancer	0.000822	0.00199	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CARD11—kidney cancer	0.000797	0.00193	CbGpPWpGaD
Tiludronate—Back pain—Doxorubicin—kidney cancer	0.000795	0.00238	CcSEcCtD
Tiludronate—Headache—Paclitaxel—kidney cancer	0.000795	0.00238	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—RAF1—kidney cancer	0.000768	0.00186	CbGpPWpGaD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—RELA—kidney cancer	0.000764	0.00185	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—RPL14—kidney cancer	0.000756	0.00183	CbGpPWpGaD
Tiludronate—Nausea—Paclitaxel—kidney cancer	0.000753	0.00225	CcSEcCtD
Tiludronate—Asthenia—Capecitabine—kidney cancer	0.000747	0.00223	CcSEcCtD
Tiludronate—PTPN1—Immune System—ITPR2—kidney cancer	0.000741	0.00179	CbGpPWpGaD
Tiludronate—Vertigo—Doxorubicin—kidney cancer	0.000739	0.00221	CcSEcCtD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000732	0.00177	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—PIK3CA—kidney cancer	0.000715	0.00173	CbGpPWpGaD
Tiludronate—Diarrhoea—Capecitabine—kidney cancer	0.000712	0.00213	CcSEcCtD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	0.000707	0.00171	CbGpPWpGaD
Tiludronate—Myalgia—Doxorubicin—kidney cancer	0.0007	0.00209	CcSEcCtD
Tiludronate—Arthralgia—Doxorubicin—kidney cancer	0.0007	0.00209	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—SFRP2—kidney cancer	0.000699	0.00169	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—SFRP2—kidney cancer	0.000699	0.00169	CbGpPWpGaD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—IL2—kidney cancer	0.000688	0.00167	CbGpPWpGaD
Tiludronate—Dizziness—Capecitabine—kidney cancer	0.000688	0.00206	CcSEcCtD
Tiludronate—ATP6V1A—Disease—ITPR2—kidney cancer	0.000684	0.00165	CbGpPWpGaD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	0.000669	0.00162	CbGpPWpGaD
Tiludronate—Headache—Capecitabine—kidney cancer	0.000652	0.00195	CcSEcCtD
Tiludronate—PTPN1—Immune System—CTSB—kidney cancer	0.000643	0.00156	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CTSD—kidney cancer	0.00064	0.00155	CbGpPWpGaD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	0.000636	0.00154	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—PSMD7—kidney cancer	0.000621	0.0015	CbGpPWpGaD
Tiludronate—Nausea—Capecitabine—kidney cancer	0.000618	0.00185	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000611	0.00183	CcSEcCtD
Tiludronate—Dyspepsia—Doxorubicin—kidney cancer	0.000591	0.00177	CcSEcCtD
Tiludronate—Pain—Doxorubicin—kidney cancer	0.000574	0.00172	CcSEcCtD
Tiludronate—ATP6V1A—Disease—PSMD7—kidney cancer	0.000573	0.00139	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CASP2—kidney cancer	0.000563	0.00136	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—AKAP13—kidney cancer	0.000563	0.00136	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CASP2—kidney cancer	0.000563	0.00136	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—AKAP13—kidney cancer	0.000563	0.00136	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—PAK1—kidney cancer	0.000557	0.00135	CbGpPWpGaD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—MAPK3—kidney cancer	0.000553	0.00134	CbGpPWpGaD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	0.000552	0.00134	CbGpPWpGaD
Tiludronate—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000549	0.00164	CcSEcCtD
Tiludronate—PTPN1—Immune System—IFNA1—kidney cancer	0.000544	0.00132	CbGpPWpGaD
Tiludronate—Abdominal pain—Doxorubicin—kidney cancer	0.00053	0.00159	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—MAPK1—kidney cancer	0.000527	0.00127	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—EGR1—kidney cancer	0.000521	0.00126	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—SLC2A1—kidney cancer	0.000518	0.00125	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—GRB7—kidney cancer	0.000515	0.00125	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—GRB7—kidney cancer	0.000515	0.00125	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—JUNB—kidney cancer	0.000515	0.00125	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—IFNA2—kidney cancer	0.000506	0.00122	CbGpPWpGaD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—KRAS—kidney cancer	0.000497	0.0012	CbGpPWpGaD
Tiludronate—Asthenia—Doxorubicin—kidney cancer	0.000481	0.00144	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—ITPR2—kidney cancer	0.000479	0.00116	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—ITPR2—kidney cancer	0.000479	0.00116	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—RAF1—kidney cancer	0.000478	0.00116	CbGpPWpGaD
Tiludronate—Diarrhoea—Doxorubicin—kidney cancer	0.000459	0.00137	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—PIK3CA—kidney cancer	0.000457	0.00111	CbGpPWpGaD
Tiludronate—Dizziness—Doxorubicin—kidney cancer	0.000444	0.00133	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—CTNNA1—kidney cancer	0.000434	0.00105	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CTNNA1—kidney cancer	0.000434	0.00105	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—HSPB1—kidney cancer	0.000432	0.00104	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—EIF4EBP1—kidney cancer	0.000432	0.00104	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—HSPB1—kidney cancer	0.000432	0.00104	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—EIF4EBP1—kidney cancer	0.000432	0.00104	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—IL2—kidney cancer	0.000429	0.00104	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CD8A—kidney cancer	0.000426	0.00103	CbGpPWpGaD
Tiludronate—Headache—Doxorubicin—kidney cancer	0.00042	0.00126	CcSEcCtD
Tiludronate—ATP6V1A—Disease—CDKN2B—kidney cancer	0.000419	0.00101	CbGpPWpGaD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—RAF1—kidney cancer	0.000414	0.001	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—TSC1—kidney cancer	0.000401	0.000971	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—ANXA1—kidney cancer	0.000401	0.000971	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—PSMD7—kidney cancer	0.000401	0.000971	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—ANXA1—kidney cancer	0.000401	0.000971	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—PSMD7—kidney cancer	0.000401	0.000971	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—TSC1—kidney cancer	0.000401	0.000971	CbGpPWpGaD
Tiludronate—Nausea—Doxorubicin—kidney cancer	0.000399	0.00119	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—FLT1—kidney cancer	0.000389	0.000941	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—FLT1—kidney cancer	0.000389	0.000941	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—VEGFA—kidney cancer	0.000364	0.000882	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—TSC2—kidney cancer	0.000362	0.000875	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—JUNB—kidney cancer	0.00036	0.000872	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—PAK1—kidney cancer	0.00036	0.000872	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—JUNB—kidney cancer	0.00036	0.000872	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—PAK1—kidney cancer	0.00036	0.000872	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—MAPK3—kidney cancer	0.000345	0.000834	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—HIF1A—kidney cancer	0.000335	0.00081	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—TSC2—kidney cancer	0.000334	0.000808	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—MAPK1—kidney cancer	0.000328	0.000794	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—KIT—kidney cancer	0.00032	0.000773	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—KRAS—kidney cancer	0.00031	0.00075	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—APC—kidney cancer	0.000295	0.000714	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—KIT—kidney cancer	0.000295	0.000714	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—IGF2—kidney cancer	0.000295	0.000713	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—IGF2—kidney cancer	0.000295	0.000713	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CDH1—kidney cancer	0.000294	0.000712	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CDKN2B—kidney cancer	0.000293	0.00071	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CDKN2B—kidney cancer	0.000293	0.00071	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—IGF1R—kidney cancer	0.000285	0.000689	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—IGF1R—kidney cancer	0.000285	0.000689	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—PIK3CA—kidney cancer	0.000285	0.000689	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—BRAF—kidney cancer	0.000277	0.000671	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—TP53—kidney cancer	0.000275	0.000666	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—RAF1—kidney cancer	0.000251	0.000607	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—RELA—kidney cancer	0.00025	0.000604	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—ERBB2—kidney cancer	0.000248	0.0006	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—MTOR—kidney cancer	0.000245	0.000592	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CD4—kidney cancer	0.000244	0.000591	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—HIF1A—kidney cancer	0.000235	0.000567	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—HIF1A—kidney cancer	0.000235	0.000567	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—TSC2—kidney cancer	0.000234	0.000566	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—TSC2—kidney cancer	0.000234	0.000566	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—RAF1—kidney cancer	0.000232	0.00056	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CDKN1B—kidney cancer	0.00023	0.000556	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—ERBB2—kidney cancer	0.000229	0.000554	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—MTOR—kidney cancer	0.000226	0.000547	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—CD4—kidney cancer	0.000226	0.000546	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—IL2—kidney cancer	0.000225	0.000544	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—KDR—kidney cancer	0.000224	0.000543	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—KDR—kidney cancer	0.000224	0.000543	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—PTGS2—kidney cancer	0.000224	0.000542	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—JUN—kidney cancer	0.000219	0.000529	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CTNNB1—kidney cancer	0.000217	0.000525	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—CDKN1B—kidney cancer	0.000212	0.000513	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—PTEN—kidney cancer	0.000212	0.000512	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—KIT—kidney cancer	0.000207	0.0005	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—APC—kidney cancer	0.000207	0.0005	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—APC—kidney cancer	0.000207	0.0005	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—KIT—kidney cancer	0.000207	0.0005	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—CTNNB1—kidney cancer	0.0002	0.000485	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—POMC—kidney cancer	0.000197	0.000476	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—POMC—kidney cancer	0.000197	0.000476	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—PTEN—kidney cancer	0.000195	0.000473	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—BRAF—kidney cancer	0.000194	0.00047	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—BRAF—kidney cancer	0.000194	0.00047	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—MAPK3—kidney cancer	0.000181	0.000437	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—MAPK1—kidney cancer	0.000172	0.000416	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—MAPK3—kidney cancer	0.000167	0.000404	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—KRAS—kidney cancer	0.000162	0.000393	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—MYC—kidney cancer	0.000162	0.000393	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—RAF1—kidney cancer	0.000162	0.000392	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—RAF1—kidney cancer	0.000162	0.000392	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—RELA—kidney cancer	0.000161	0.000391	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—RELA—kidney cancer	0.000161	0.000391	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—ERBB2—kidney cancer	0.00016	0.000388	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—ERBB2—kidney cancer	0.00016	0.000388	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—MAPK1—kidney cancer	0.000159	0.000384	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—MTOR—kidney cancer	0.000158	0.000383	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—MTOR—kidney cancer	0.000158	0.000383	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—KRAS—kidney cancer	0.00015	0.000363	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—PIK3CA—kidney cancer	0.000149	0.000361	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CDKN1B—kidney cancer	0.000149	0.000359	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CDKN1B—kidney cancer	0.000149	0.000359	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—IL2—kidney cancer	0.000145	0.000352	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—IL2—kidney cancer	0.000145	0.000352	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CCND1—kidney cancer	0.000142	0.000343	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CCND1—kidney cancer	0.000142	0.000343	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—JUN—kidney cancer	0.000141	0.000342	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—JUN—kidney cancer	0.000141	0.000342	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CTNNB1—kidney cancer	0.00014	0.00034	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CTNNB1—kidney cancer	0.00014	0.00034	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—PIK3CA—kidney cancer	0.000138	0.000333	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—PTEN—kidney cancer	0.000137	0.000331	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—PTEN—kidney cancer	0.000137	0.000331	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—VEGFA—kidney cancer	0.000124	0.000299	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—VEGFA—kidney cancer	0.000124	0.000299	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—MAPK3—kidney cancer	0.000117	0.000283	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—MAPK3—kidney cancer	0.000117	0.000283	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—MYC—kidney cancer	0.000114	0.000275	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—MYC—kidney cancer	0.000114	0.000275	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—MAPK1—kidney cancer	0.000111	0.000269	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—MAPK1—kidney cancer	0.000111	0.000269	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—KRAS—kidney cancer	0.000105	0.000254	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—KRAS—kidney cancer	0.000105	0.000254	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—PIK3CA—kidney cancer	9.65e-05	0.000233	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—PIK3CA—kidney cancer	9.65e-05	0.000233	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—TP53—kidney cancer	9.34e-05	0.000226	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—TP53—kidney cancer	9.34e-05	0.000226	CbGpPWpGaD
